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Molecular Interaction Fields vs. Quantum-Mechanical-based 
descriptors in the modelling of lipophilicity of platinum(IV) complexes 
Giuseppe Ermondi,a Giulia Caron,a Mauro Ravera,b Elisabetta Gabano,b Sabrina Bianco,b James A. 
Platts,c Domenico Osella*,b 
We report QSAR calculations using VolSurf descriptors to model the lipophilicity of 53 Pt(IV) 5 
complexes with a diverse range of axial and equatorial ligands. Lipophilicity is measured using an 
efficient HPLC method. Previous models based on a subset of this data are shown to be inadequate, due 
to incompatibility of whole molecule descriptors between axial carboxylate and hydroxo ligands. Instead, 
the interaction surfaces of complexes with various probes are used as independent descriptors. Partial 
least squares modelling using three latent variables results in an accurate (R2 = 0.92) and robust model 10 
(Q2 = 0.87) of lipophilicity, that moreover highlights the importance of size and hydrophobicity terms and 
the modest relevance of hydrogen bonding. 
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Introduction  
It is well know that similar molecules, with just minor structural 
variations, can exhibit dramatically different biological 
behaviour. Consequently, the development of the quantitative 
structure-activity relationships (QSAR), i.e. mathematical 5 
relationships linking chemical structure and pharmacological 
activity, help the chemists to design out negative properties and 
incorporate positive attributes to the molecules under 
investigation. The final goal is to design potentially active 
compounds prior to their synthesis, and to discharge drug 10 
candidates with unfavourable pharmacokinetic/pharmacodynamic 
profiles, thus limiting the amount of in vitro and in vivo 
experiments required in drug discovery and optimisation. 
 Considering the complexity of the ADME (Absorption, 
Distribution, Metabolism and Excretion) prediction of drug 15 
candidates, today the original dependent variable “A” in QSAR, 
representing the desired therapeutic effect, may be replaced by 
other, generic properties “P” (QSPR, i.e. quantitative structure-
property relationship) in order to limit the extension of 
calculations.1 In this context lipophilicity is a key feature because 20 
it is directly related to the ability of a molecule to cross passively 
cell membranes.2,3 The partition coefficient log Po/w is widely 
used to represent molecular lipophilicity because it measures the 
differential solubility of a compound between n-octanol (a model 
of the lipid bilayer of a cell membrane) and water (the solvent in 25 
and out of cells). The importance of this parameter is confirmed 
by the fact that log Po/w is one of the properties identified by 
Lipinski in the “Rule of 5” for drug-like molecules.4 Lipophilicity 
of a molecule is generally thought to arise from its size and 
polarity. Thus, a large, apolar molecule will have a tendency to 30 
partition into the organic phase, where formation of cavities is 
easier, while a more polar molecule will tend to partition into 
water, the more polar and hydrogen bonding solvent.5 
 Although a lipophilicity experiment, by using the traditional 
shake-flask method seems at a first glance simple and easy, it is 35 
not a trivial matter because data can vary significantly with 
experimental conditions. The main difficulty in the shake-flask 
method comes from the significant errors affecting the final 
log Po/w in the case of extreme values (i.e. very polar or very 
lipophilic compounds), that comes from an unbalanced partition 40 
in favour of the aqueous or the organic phase, respectively. This 
is the case of the well-known Pt(II)-based antitumor drug 
cisplatin and its analogues, characterized by quite negative 
log Po/w values. Moreover the shake-flask method is generally 
slow, expensive and, sometimes, poorly reproducible.  45 
 For these reasons, alternative experimental methods have been 
developed to measure the lipophilicity. Among them, the 
retention parameters in RP-HPLC (where n-octanol is ideally 
replaced by the C18 chains functionalizing silica as stationary 
phase, while the mobile phase consists of various mixtures of 50 
water and organic co-solvents) are often used, even if criticized 
by some authors as not truly replacing the shake-flask method.6,7,8 
Since RP-HPLC retention is due to partitioning between (polar) 
mobile and (apolar) stationary phases, there is a straightforward 
correlation between the partition coefficient and the HPLC 55 
capacity factor k’ (k’ = (tR – t0) / t0, where t0 is the retention time 
for an unretained compound and tR is the retention time of the 
analyte). The log k0 (k’0 is the HPLC capacity factor extrapolated 
to 100% water) values of compounds with known log Po/w, can be 
used to create a calibration curve (log Po/w = a log k'0 + b) to 60 
evaluate partition coefficients from chromatographic data. 
 Historically, log Po/w values are preferred because one would 
like to have a comparison with standard experimental 
lipophilicity values or with calculated log P values. However, 
log k’0 is a good lipophilicity index per se and is generally used 65 
because of its direct correlation with log Po/w values. Moreover, 
being obtained only in an experimental way log k’0 does not 
require any conversion, in such a way that no further 
experimental error is introduced in the final lipophilicity value. 
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Fig. 1 Sketch of the complexes under study: the dihydroxido complexes 1-22 are reported here for the first time, while complexes 23-53 were previously 
studied. 16,25 
 
 In recent years octahedral Pt(IV) complexes have emerged as 5 
an alternative to traditional cisplatin-like compounds. They are 
generally considered antitumor pro-drugs that can be reduced in 
vivo to the active Pt(II) metabolite loosing the axial ligands (L) in 
the hypoxic tumor milieu.9 These compounds are more inert to 
ligand substitution reactions than Pt(II) counterparts, leading to 10 
lower systemic toxicity from unwanted side-reactions and 
increasing the likelihood of the drug reaching its cellular target. 
Interestingly, Satraplatin (trans,cis,cis-
bis(acetato)ammine(cyclohexylamine) dichloridoplatinum(IV), 
JM216) is actually on clinical trials as orally active antitumor 15 
drug.10  
Dihydroxido Pt(IV) complexes represent an interesting sub-class 
of Pt(IV) compounds.11 In clinical experience iproplatin 
(cis,trans,cis-dichloridodihydroxidobis(isopropylamine) 
platinum(IV), also nicknamed CHIP or JM9) demonstrated 20 
excellent activity in several phase II trials.12,13,14 However, this 
compound was abandoned due to the lack of any superior 
performance with respect to cisplatin.15  
 In a previous study, a relationship between cytotoxicity and 
both reduction potential Ep and partition coefficient log Po/w of 25 
Pt(IV) complexes has been established: the easier the reduction 
and the higher the lipophilicity, the higher the cytotoxicity.16 
These two chemico-physical properties, in turn related to cellular 
uptake and activation by reduction in cytosol, can be tuned 
through choice of the six ligands around the Pt(IV) centre, 30 
especially the axial ones.11,17. These ligands can also act as 
carriers or adjuvant agents, offering interesting applications in the 
controlled release and in the drug targeting and delivery.18 
 The ability to predict relevant physicochemical properties of 
platinum complexes directly from their structures would 35 
represent an important step in rational design of new platinum 
drugs, allowing potential candidates to be proposed before 
lengthy synthesis and testing. In the literature a limited number of 
publications report on models to predict log Po/w values of 
Pt(II)19,20,21,22,23,24 and Pt(IV)20,22,24 complexes by using different 40 
descriptors and, more importantly, different mathematical 
approaches. In this framework, a statistically accurate model for 
the prediction of log Po/w of a series of Pt(IV) complexes 
containing carboxylates or chlorides as axial ligands has been 
recently published by us. A combination of surface area and 45 
atomic charges was necessary to build the model.25 This study 
also demonstrated the ability of the PM6 semi-empirical method26 
to accurately reproduce the X-ray geometry of Pt(IV) complexes 
such as those discussed here. 
 In order to evaluate the applicability of the above-reported 50 
model to other Pt(IV) complexes, a new set of compounds has 
been studied. In the present work 22 dihydroxido Pt(IV) 
complexes (1-22 in Figure 1) have been newly synthesised or, in 
some cases, re-synthesised according to standard 
methods.27,28,29,30 Their extrapolated capacity factors log k’0 were 55 
measured and in silico properties evaluated by QSRR 
(Quantitative Structure-Retention Relationship) methods together 
with the previously studied Pt(IV) complexes (23-53 in Figure 1). 
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Fig. 2 The score plot of the first two main PCs (in parentheses the variance %): A) QM descriptors, B) VolSurf descriptors 
 
Results and Discussion 
Synthesis and characterization of Pt(IV) complexes 5 
The dihydroxido Pt(IV) complexes 1-22 were obtained by 
oxidation30 of the parent Pt(II) compound27,28,29 with hydrogen 
peroxide (see supporting information for the details of the 
syntheses). The samples contained residual H2O2, removed by 
washing the compounds several times with cold water. All the 10 
dihydroxido Pt(IV) complexes, except compounds 5-8, are poorly 
soluble in water. Figure 1 shows the entire set of the studied 
complexes. 
Determination of extrapolated capacity factors, log k’0 
All the 22 dihydroxido complexes under study were injected into 15 
RP-HPLC and their log k’0 values, i.e. the capacity factor 
extrapolated to 0% of organic co-solvent, namely MeOH, were 
measured (Table 1). To obtain a more general QSRR relationship, 
the log k’0 values of other 31 Pt(IV) complexes, determined in the 
same experimental conditions were added in this study.25 The 20 
log k’0 of the entire series of Pt(IV) complexes cover a wide 
range of values (ca. 8 log units). The increase of the lipophilicity 
is expected to enhance cellular uptake by passive diffusion.20,31,32 
Table 1 log k’0 values for the complete 1-53 series of Pt(IV) complexes 
Cmpd log k’0a Cmpd log k’0a Cmpd log k’0a 
1 -0.97 19 0.23 37 2.29 
2 -0.50 20 -0.56 38 3.53 
3 0.64 21 0.98 39 -0.46 
4 -0.90 22 0.58 40 -0.16 
5 -0.75 23 -0.78 41 0.31 
6 -0.55 24 -0.66 42 1.98 
7 -0.24 25 0.37 43 5.11 
8 -0.08 26 -0.25 44 3.83 
9 1.20 27 0.68 45 -0.83 
10 2.16 28 1.72 46 -0.51 
11 2.84 29 2.94 47 1.34 
12 -0.96 30 4.22 48 1.60 
13 -0.75 31 -0.60 49 4.56 
14 -0.89 32 -0.70 50 6.98 
15 -0.50 33 -0.06 51 1.60 
16 0.19 34 -0.32 52 3.70 
17 -0.58 35 0.40 53 4.26 
18 -0.63 36 1.29   
a log k’0 for complexes 23-53 are from ref. 
25 25 
 
QSRR analysis 
The log k’0 of some compounds of the series (23-53) was 
successfully modelled with a limited set of QM descriptors.25 The 
same approach failed when applied to the whole series of 1-53 30 
complexes. This is probably due to the increased heterogeneity of 
the training set, in turn due to the different axial ligands present 
in 1-22 with respect to 23-53 compounds (OH instead of 
carboxylates) that enormously enlarge the chemical domain of the 
molecules. This is shown by the analysis of the score plot of the 35 
Principal Component Analysis (PCA) based on QM descriptors 
(Figure 2). PCA is a general tool for the interpretation of large 
data tables, in which the number of the original variables is 
reduced by a projection of the objects (i.e. the molecules) onto a 
smaller number of new variables termed principal components 40 
(PC).  
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Fig. 3 MIF generated by the OH2 probe at -5.0 kcal mol-1 (left) and by the DRY probe at -0.2 kcal mol-1 (right) for compound 15. 
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Fig. 4 Correlation between experimental (Exp) and calculated (Calc) 
log k’0. 5 
 The PCs are orientated so that the first PC describes as much 
as possible of the original variation between the objects. The 
second PC is orientated in an orthogonal manner to the first PC 
and is directed to describe as much as possible of the remaining 
variation and so on. The projection of objects onto a PC is called 10 
score. By plotting the scores for two PCs it is possible to 
graphically find similarities and differences between objects. 
Figure 2A shows that the two main PCs (PC1 and PC2) based on 
the QM descriptors split the whole series of compounds in the 
two groups (1-22 and 23-53) characterised by different kind of 15 
axial ligands. This result confirms that the previolusly selected 
series of QM descriptors (Table S1)25 are not suited to 
exhaustively model the chromatographic behaviour of the whole 
series of platinum complexes. 
 A totally different approach has been attempted, replacing QM 20 
descriptors with descriptors based on 3D molecular fields, i.e. 
VolSurf descriptors.33,34 Briefly, VolSurf is a computational 
procedure to find out molecular descriptors from 3D molecular 
interaction fields (MIFs)35 obtained employing the GRID force 
field.36,37,38 Interaction fields are obtained with different probes 25 
and the surface of the regions that encompass interaction energy 
values under certain cutoff limits are calculated. In particular, 
water (OH2) , hydrophobic (DRY), hydrogen bond donor (HBD, 
amide N1) and hydrogen bond acceptor (HBA, carbonyl O) 
probes have been considered in the present work. 30 
 Since VolSurf descriptors represent polarity and 
hydrophobicity (as well as size and shape) of molecules, they are 
generally well suited for the modelling of lipophilicity indexes.39 
This was shown in previous studies where robust QSRR models 
based on VolSurf descriptors were used to model the variation of 35 
different chromatographic lipophilicity indexes.40,41 Figure 2B 
confirms the suitability of the application of VolSurf descriptors 
to the whole series of investigated complexes, with no 
discrimination of carboxylate, chloride or hydroxo species. As an 
example, Figure 3 shows the visual representation of two of the 40 
92 VolsSurf descriptors obtained with OH2 and DRY probes. 
They represent the volume of the molecular envelope which is 
accessible to, and interacts attractively with OH2 probe at -5.0 
kcal mol-1 and with the DRY probe at -0.2 kcal mol-1 for 
compound 15 (see Experimental for details and Supporting 45 
Information for more envelopes). 
 A relationship between log k’0 and the VolSurf descriptors was 
obtained by Partial Least Squares (PLS) regression technique. A 
three latent variables (3LVs) model was found: the three main 
components explained about 90% of the total variance (R2 = 0.92) 50 
while the root mean square of the errors (RMSE) was 0.3. To 
validate these models internal validation was firstly used. 
Whereas some researchers in the QSAR field support internal 
validation, others consider that internal validation is not a 
sufficient test to check the robustness of models, and external 55 
validation is necessary.42 In this case, however, since the sample 
size is relatively small, and thus holding a portion of it back for 
testing would be wasteful, it was preferred to use cross-
validation, with multiple rounds using different partitions. 
 In particular the 53 compounds were assigned in a random way 60 
 8  
to N groups, each one containing an equal (or nearly equal) 
number of compounds. Then models were built keeping one of 
these groups out of the analysis until all of the compounds were 
kept out once. The formation of the groups and the validation was 
repeated 50 times. Results were similar with different partitions: 5 
Q2 (LOO) = 0.87; Q2 (N = 4) = 0.85; Q2 (N = 3) = 0.85.  
 Finally, to further validate PLS model the order of Y values 
which produced unacceptable R2 and Q2 values was randomized 
(data not shown). 
The relationship between experimental and calculated values is 10 
shown in Figure 4. A slope of approximately 1 and an intercept of 
about 0 indicate a very good correspondence between 
experimental and calculated values. 
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Fig. 5 BR(+) and BR(-) for PLS model of log k’0. 15 
 The main drawback of PLS models is the difficulty of their 
interpretation from the chemical standpoint. The Variable 
Importance in Projection (VIP) plots are often used to overcome 
this limit.43 Briefly, the VIPs show which descriptors are the most 
important for the model, whereas the sign of the PLS coefficients 20 
indicates the positive or negative contribution of the descriptor to 
the investigated variable. However the use of VIPs for model 
interpretation is somewhat subjective and therefore it remains of 
difficult understanding. 
 Recently, some of us described a new method to obtain a 25 
mechanistic interpretation of PLS models by introducing the 
concept of block of descriptors.41 This approach can be applied to 
any set of molecular descriptors but is particularly suited for 
VolSurf+ descriptors. Since technical reasons prevent to use 
VolSurf+ software with platinum complexes, here we slightly 30 
modified the method above described to adapt it to VolSurf 
descriptors. The relevance of any block of descriptors to the PLS 
model is calculated by the Block Relevance (BR) parameter (see 
Experimental part). Table 2 lists the BR values for the model 
discussed above, and demonstrates that log k’0 is mainly 35 
characterized by the block of size descriptors (BR = 3.24), which 
is at least twice as important as any other block.41  
Table 2 BR values for VolSurf PLS model of log k’0. 
Block N° Descriptors BR 
Size 7 3.24 
Water 23 0.74 
DRY 16 1.46 
HBA 15 0.35 
HBD 15 0.58 
Others 16 0.94 
 
To take into account the sign of the PLS coefficient, BR is split in 40 
BR(+) relating to retention in the stationary phase, and in BR(-), 
relating to retention in the mobile phase (see Experimental part). 
Figure 5 shows the trend of BR(+) and BR(-) for the investigated 
system. A positive coefficient means that an increase of the block 
of the considered descriptors causes an increase in log k’0 (and 45 
thus the retention in stationary phase); the reverse is true for 
negative coefficients. The relevance of the block of size and 
hydrophobic descriptors (Figure 5) indicates that the lipophilicity 
of these complexes is mainly driven by the ligands rather than by 
platinum(IV) core properties. The importance of this block of 50 
descriptors, and their positive sign, is consistent with established 
ideas of the molecular properties that affect lipophilicity.5 It is 
noteworthy that this conclusion can be drawn only using MIFs 
based descriptors because of the limits of QM descriptors in the 
modelling of chromatography behavior of platinum complexes. 55 
Experimental 
General 
K2[PtCl4] (Johnson Matthey and Co.) and all other chemicals 
(Aldrich) were used without further purification.  
 The multinuclear NMR spectra were measured on a JEOL 60 
Eclipse Plus operating at 400 MHz (1H), 100.5 MHz (13C) and 
85.9 MHz, respectively. 1H and 13C NMR chemical shifts were 
reported in parts per million (ppm) referenced to solvent 
resonances; for measurements in D2O 1% methanol was added as 
internal reference. 195Pt NMR spectra were recorded using a 65 
solution of K2[PtCl4] in saturated aqueous KCl as the external 
reference. The shift for K2[PtCl4] was adjusted to -1628 ppm 
from Na2[PtCl6] ( = 0 ppm). 
 RP-HPLC and mass analysis were performed using a Waters 
HPLC-MS instrument equipped with Alliance 2695 separations 70 
module, 2487 dual lambda absorbance detector, and 3100 mass 
detector. Electrospray ionization mass spectra (ESI-MS) were 
obtained delivering a diluted solution of the compound in 
methanol directly into the spectrometer source at 0.01 mL 
min−1.44 The source and desolvation temperatures were set to 150 75 
and 250 °C, respectively, with nitrogen used both as a drying and 
a nebulizing gas. The cone and the capillary voltages were 
usually 30 V and 2.70 kV, respectively. Quasi-molecular ion 
peaks [M+H]+ or sodiated [M+Na]+ peaks were assigned on the 
basis of the m/z values and of the simulated isotope distribution 80 
patterns. 
 Purity of compounds was assessed by analytical RP-HPLC 
(see below), elemental analysis and determination of Pt content 
by inductively coupled plasma-optical emission spectroscopy 
(ICP-OES). Elemental analyses were carried out with a EA3000 85 
CHN Elemental Analyzer (EuroVector, Milano, Italy). Platinum 
was quantified by means of a Spectro Genesis ICP-OES 
spectrometer (Spectro Analytical Instruments, Kleve, Germany) 
equipped with a crossflow nebulizer. In order to quantify the 
platinum concentration the Pt 299.797 nm line was selected. A 90 
platinum standard stock solution of 1000 mg L-1 was diluted in 
1.0% v/v nitric acid to prepare calibration standards. 
Synthesis of platinum complexes 
The dihydroxido Pt(IV) complexes 1-22 (Figure 1) were obtained 
by oxidation with hydrogen peroxide30 of the parent Pt(II) 95 
compound obtained from the Dhara’s method and its 
adaptations.27,28,29 Briefly, K2[PtI4] was produced in solution by 
reaction of K2[PtCl4] (1 mmol) and KI (6 mmol), and reacted 
with an amine ligand (3.3 mmol for monodentate amines, A, and 
1.7 mmol for bidentate ones, A2) to give the cis-[PtA2I2] 100 
precipitate. This was isolated by centrifugation and washed with 
water, ethanol and diethyl ether. Upon reaction with AgNO3 (1.96 
mmol) or Ag2SO4 (0.98 mmol), the corresponding diaqua 
intermediate was formed. After removal of AgI, the diaqua 
species reacted with chlorides or carboxylates to yield the final 105 
Pt(II) complex. The yields were from 70 to 85%. This complex 
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(0.5 mmol) reacted with a tenfold excess of 35% hydrogen 
peroxide (440 μL) in water at RT for 24 h. The solvent was then 
removed under reduced pressure and the dihydroxido product was 
collected as a pale yellow solid, which was washed with cold 
water, methanol and diethyl ether and dried in vacuum. The 5 
yields were from 50 to 70% (see Electronic Supplementary 
Information for details). 
RP-HPLC method 
Chromatographic analysis were used to evaluate the purity and 
the capacity factors of the compounds. The chromatographic 10 
conditions were:19 silica-based C18 stationary phase (5 µm 
Gemini® C18 column 253 mm ID); mobile phase containing 15 
mM HCOOH aqueous solution with different percentage of 
MeOH (flow rate = 0.75 ml min-1; isocratic elution, UV-visible 
detector set at 210 nm). KCl was the internal reference to 15 
determine the column dead-time (t0).45 Platinum complex 
solutions were 0.25 mM. A chromatogram for each complex with 
every different eluant composition has been performed (the 
methanol fraction, , ranging from 20 to 70%) and the 
corresponding retention time tR was used to calculate log k’ (k’ = 20 
(tR – t0) / t0). 
 From these data, the extrapolation of the log k’ to 0% MeOH 
(log k’0), corresponding to the capacity factor in pure water, for 
all compounds has been performed (Eq. 1).16,25,46 
log k’ = log k’0 - S  (1) 25 
where S is a solute-dependent solvent strength specific to the 
organic modifier on the stationary phase under consideration. 
Quantum-Mechanical (QM) descriptors 
Surface area, volume, PSA (surface sum over oxygen and 
nitrogen atoms), frontier orbital energies, dipole moment and 30 
atomic partial charges were extracted from the PM626 
(MOPAC2009, http://openmopac.net/ and Spartan 08, 
Wavefunction, Irvine, CA, USA) fully optimised geometries of 
complexes 1-22 (see Table S1, Electronic Supplementary 
Information). The same set of data for 23-53 was taken from the 35 
literature.25  
Principal Component Analysis (PCA) 
PCA was performed using Simca v.13 (Umetrics Sweden) 
VolSurf model 
Pt(IV) parameterization in the GRID force field implemented in 40 
VolSurf v.4.1.2 software (http://www.moldiscovery.com/) was 
performed according to a procedure similar to that described 
elsewhere for Pt(II).39 The geometries of fully optimized 
complexes were saved in mol2 format and submitted to GRID to 
obtain the molecular interaction fields (MIFs). The binary .kont 45 
files of all structures were then submitted to VolSurf for the 
calculation of the 92 VolSurf descriptors. These were extracted 
from MIFs obtained with the water (OH2), hydrophobic (DRY), 
hydrogen bond donor (HBD, amide N1) and hydrogen bond 
acceptor (HBA, carbonyl O) probes. Partial Least Squares (PLS) 50 
analysis was used as implemented in the VolSurf software. 
 Chemical interpretation of the PLS model was performed as 
described in the details elsewhere using VolSurf+ descriptors.39,40 
Since for technical reasons VolSurf+ descriptors for platinum 
complexes cannot be calculated, here we used VolSurf 55 
descriptors. These latter were grouped in six blocks: a) 
descriptors that characterize the size and shape of the solute (7 
descriptors in the text, briefly called size, color-code green), b) 23 
descriptors that express the solute’s interaction with water 
molecules (in the text indicated as water, colour-code light blue), 60 
c) 15 descriptors that describe the solute’s ability to form 
hydrogen bond interactions with the donor group of the probe 
(that mimics the chromatographic system, colour-code blue, see 
below), d) 15 descriptors expressing the solute’s ability to form 
hydrogen bond interactions with the acceptor group of the probe 65 
(that mimics the chromatographic system, colour-code red, see 
below), e) 16 descriptors describing the solute’s propensity of the 
solute to participate in hydrophobic interactions (in the text called 
DRY for short, colour-code yellow), f) 16 descriptors mainly 
describing the imbalance between hydrophilic and hydrophobic 70 
regions (in the text called others, colour-code grey). More details 
about the significance of the descriptors can be found in the 
original paper.40  
 Block Relevance (BR) was defined as the ratio of the sum of 
the squared Variable Importance Projection (VIP) values of a 75 
given block of descriptors and the number of those descriptors 
(Eq. 2). 
i
N
j j
i
N
VIP
BR
i
 

1
2
  (2) 
where i is the number of blocks (6 here, Table 2), N is the number 
of descriptors for any block, VIP is the value of each predictor 80 
fitting the PLS model. The higher the value of BR, the more 
important is that block. 
 Depending on the sign of the PLS coefficient, BR was broken 
down into BR(+) relating to retention in the stationary phase, and 
BR(-), relating to retention in the mobile phase (Eq. 3). 85 
BRi = BRi(+) + BRi(-)  (3) 
Conclusions 
We report the HPLC measurement and QSRR modelling of 53 
Pt(IV) complexes as models of potential anti-cancer pro-drugs. 
New values of log k’0 for 22 dihydroxo complexes have been 90 
measured, and combined with 31 previously reported values to 
result in a large and diverse set of complexes whose lipophilicity 
spans 8 orders of magnitude, and hence act as a stringent test of 
possible statistical models. We show that conventional models 
based on whole molecule properties, extracted from semi-95 
empirical PM6 calculations, are incapable of modelling this 
larger dataset, in contrast to an earlier study. In contrast, sampling 
to the interaction of each complex with a series of probes and 
using these interactions as independent variables results in an 
accurate and robust model. This VolSurf model, using three latent 100 
variables, not only correlates and predicts lipophilicity with good 
accuracy, but also highlights the molecular properties that 
determine lipophilicity, showing size and hydrophobic 
interactions to play major roles. This study confirms the 
superiority of VolSurf over QM descriptors to model lipophilicity 105 
of platinum (IV) complexes, and suggests that they have excellent 
potential in modelling biologically active transition metal 
complexes in general. 
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